1. Introduction {#sec1}
===============

Ketamine is a broadly used anaesthetic for analgosedation, especially during sepsis and cardiovascular instability. Intraoperative pulmonary edema has been reported worldwide following intramuscular or intravenous ketamine administration \[[@B1]--[@B5]\]. Pulmonary edema is the abnormal fluid accumulation in the interstitial or alveolar spaces of the lung. Active Na^+^ reabsorption across lung epithelia requires the sequential coordination of the entry of Na^+^ ions through Na^+^-selective, amiloride-sensitive epithelial Na^+^ channels (ENaC) located at the apical membranes, followed by the extrusion across the basolateral membranes by the energy-consuming Na^+^-K^+^-ATPase. The entry of Na^+^ ions through apical membranes is thought to be the critical step in this process \[[@B6]--[@B9]\].

Traditional teaching is that pulmonary edema occurring in patients tends to be cardiac in aetiology, usually with left heart dysfunction which caused back pressure across the pulmonary system, and led to extravasation of fluid into the alveolar space. In patients undergoing anaesthesia, higher afterload as in neurogenic causes or other noncardiogenic pulmonary edema are also encountered \[[@B1]--[@B3]\]. Ketamine can clinically induce lung edema as well as increase pulmonary vascular permeability and arterial pressure. However, the effects of ketamine on alveolar Na^+^ transport in human lungs are not known. Alveolar fluid clearance (AFC) has been widely used in understanding lung fluid balance, not only under normal but also pathologic conditions, for example, in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Stimulation of AFC accelerates the resolution of pulmonary edema, which benefits gas exchange across the alveolar epithelium \[[@B10]\]. In contrast, impairment of AFC is often related with worsened survival in ALI and ARDS patients \[[@B11], [@B12]\], which leads to the development of pulmonary edema \[[@B13]\]. In this paper, we evaluated whether AFC of fluid-instilled human lung lobes is impaired when ketamine is administered into the alveolar space *ex vivo*, aiming to find the role of ketamine in lung epithelial fluid transport.

As we know, lung alveolar tissue from human is not readily available, and the use of isolated alveolar cells from other species has inherent disadvantages due to species variation. Other problems with acutely isolating cells are possible contamination by microorganisms and damage to the channel proteins by the digestive processes that is necessary for dissociation. A549 cell line is originated from a human alveolar cell carcinoma and possesses many characteristics of Type II alveolar cells \[[@B14]\], which can synthesize phospholipids, consistent with the well-described function of Type II alveolar cells-synthesis of pulmonary surfactant \[[@B15], [@B16]\]. Here, we used whole-cell patch clamp technique to identify the effects of ketamine on vectorial Na^+^ transport in A549 cells *in vitro*. Our results demonstrate that ketamine can inhibit ENaC and decrease ENaC-associated fluid clearance across the distal lung epithelium.

2. Methods and Materials {#sec2}
========================

2.1. *Ex Vivo* Human Lung Study {#sec2.1}
-------------------------------

Human lungs were obtained from patients who underwent pneumonectomy for lung cancer (Department of Thoracic surgery, First Affiliated Hospital of China Medical University, Shenyang, China). This study was approved by the responsible ethics committee and by written informed patient consent. There were no pulmonary fibrosis or emphysema as assessed by preoperative computed tomograms. The lung samples excised from patients exposed to stimulants were excluded for our study. Preoperative pulmonary function tests were normal in all patients (see [Table 1](#tab1){ref-type="table"}). The surgical procedure and lung segment chosen were done as described previously \[[@B17], [@B18]\]. Briefly, immediately after removal of the lung, we occluded the segmental bronchus with a 10-Fr. balloon catheter and then chose a segment furthest away from the tumor. A warmed normal saline solution (20 mL, 37°C) containing 5% bovine serum albumin with or without amiloride (1 mM) or ketamine (racemate, 100 *μ*M) was instilled into the distal air spaces through the catheter. We understand that *iv* perfusion of ketamine will mimic the clinical circumstance. Unfortunately, ketamine cannot be applied *via* blood vessels of excised human lung lobes due to incompleted pulmonary circulation. Instead, the advantage of intratracheal delivery is that we are able to examine the direct effects of ketamine on alveolar epithelial function. After instillation, the lung segments were inflated with 100% oxygen at an airway pressure of 7 cm H~2~O. The temperature in this experiment was kept 37°C controlled by a waterbath. Alveolar fluid was aspirated 60 min later and then was centrifuged at 6500 rpm for 10 min, and the supernatant was used for measuring protein concentrations.

2.2. Measurement of Alveolar Fluid Clearance {#sec2.2}
--------------------------------------------

In the human lung study, the protein concentrations in aspirated solutions were measured by Bradford Method. We estimated AFC by the changes of concentration for bovine serum albumin as water was absorbed. AFC was calculated by the following equation:  AFC = \[(*V*i − *V*f)/*V*i\] × 100, where *V* is the volume of the instilled bovine serum albumin solution (i) and the final alveolar fluid (f). *V*f = *V*i × *P*i/*P*f, where *P* represents the protein concentration in the instilled bovine serum albumin solution (i) and the final alveolar fluid (f).

2.3. Cell Culture {#sec2.3}
-----------------

A549 cells were obtained from the American Type Culture Collection (ATCC) and grown in RPMI medium (ATCC) supplemented with 10% fetal bovine serum, penicillin (100 units/mL), and streptomycin (100 *μ*g/mL). Cells were seeded in 75 cm^2^ flasks and incubated in a humidified atmosphere of 5% CO~2~, 95% O~2~ at 37°C. For patch clamp studies, cells were lifted by 0.25% trypsin and 0.53 mM EDTA (Sigma), then seeded at a density of 1 × 10^6^ cells/mL on round coverslips (8 mm, WPI) situated in 24-well culture plates. Cells were grown in the above medium supplemented with 200 nM dexamethasone to facilitate sodium channel differentiation, the medium was replaced every other day.

2.4. Patch Clamp Recordings {#sec2.4}
---------------------------

Immediately before each experiment, a coverslip bearing A549 cells was removed from the culture dish and put into a recording chamber, which was mounted on the stage of an inverted fluorescent microscope (Leica DM IRB). For whole-cell mode of patch clamp recording, cells were perfused continuously with extracellular fluid containing (in mM): 140 NaCl, 1.8 CaCl~2~, 1 MgCl~2~, and 10 HEPES (pH 7.2) \[[@B19]\], following being exposed to ketamine (30 to 1,000 *μ*M) and the Na^+^ channel blocker amiloride (10 *μ*M), transepithelial transport indicated by amiloride-sensitive currents were measured. Pipettes were made from capillary glass electrode with a P-97 micropipette puller (Sutter). They were back-filled with internal solution (in mM): 100 K-gluconate, 40 KCl, 2 MgCl~2~, 0.5 CaCl~2~, 2 K~2~ATP, 4 EGTA, and 10 HEPES (pH 7.2) \[[@B20]\]. The pipette resistance varied from 5 to 10 MΩ when filled with this intracellular fluid. Offset potential was corrected before a gigaohm seal formation. Series resistance and capacitance transients were then compensated with an Axopatch 700B amplifier (Molecular Devices). Currents were digitized with a Digidata 1440A converter (Molecular Devices), filtered through an internal four-pole Bessel filter at 1 kHz, and sampled at 2 kHz. Inward and outward whole-cell currents were elicited by employing a step-pulse protocol from −120 mV to +80 mV in 20 mV increments every 10 s for 500 ms duration at a holding potential of −40 mV. Steady-state currents were averaged between 100 and 200 ms and only the cells with stable baseline currents were included in the results.

2.5. Statistics {#sec2.5}
---------------

Electrophysiological data from patch clamp studies were primarily analyzed with the Clampfit 10.0 (Molecular Devices) software. Furthermore, the measurements were imported into OriginPro 8.0 software (OriginLab) for statistically computation and graphic plotting. Amiloride-sensitive currents (AS) are defined as the difference between total current and amiloride-resistant current. The IC~50~ values of ketamine inhibition were calculated by fitting the dose-response curve with the Hill equation. The whole-cell currents among each single A549 cell were divergent due to various cell size (capacitance), passage, and culture reagents. Thus the whole-cell channel activity was presented as amiloride-sensitive whole-cell current density (ASI~density~, pA/pF) or normalized currents to the one at −100 mV of control group.

For analyses of *ex vivo* alveolar fluid clearance, the mean and SE values of amiloride-sensitive AFC fractions were computed as previously reported \[[@B21]\].

All results are presented as mean ± SEM. One-way ANOVA computations were used to analyze the difference of the means for normally distributed data. Mann-Whitney test was applied for nonparametric data. *P* \< 0.05 was considered as significant.

3. Results {#sec3}
==========

3.1. Ketamine Reduces AFC in Human Lungs *Ex Vivo* {#sec3.1}
--------------------------------------------------

To examine the potential effects of ketamine on fluid resolution in distal lung air spaces, we measured AFC in human lung lobes *ex vivo* under physiological conditions. The clinical data of the patients are summarized in [Table 1](#tab1){ref-type="table"}. Pulmonary function tests were normal in all patients and there were no significant statistic differences among the four groups.

As shown in [Figure 1(a)](#fig1){ref-type="fig"}, the normal AFC for 5% bovine serum albumin control group was 14.4 ± 1.9% (*n* = 6). These result consisted with previous observations as well as our recent publication in normal human lungs \[[@B22], [@B23]\]. Intratracheal instillation of ketamine (100 *μ*M) markedly decreased the reabsorption of the 5% BSA instillate (10.2 ± 3.6%,  *P* \< 0.05 versus control,  *n* = 5). We asked the question of whether ketamine inhibits ENaC activity. To address this issue, we applied a specific ENaC inhibitor, amiloride (1 mM). This compound reduced AFC to 6.6 ± 2.8% (*P* \< 0.01 versus control,  *n* = 5). Ketamine (keta + amil) did not further reduce fluid resolution significantly (9.3 ± 3.7%, *P* \> 0.05 versus ketamine group, *n* = 5). Under these experimental conditions, ketamine can only alter AFC fractions contributed by non-ENaC pathways. These data suggest that ketamine could almost completely decrease amiloride-sensitive fraction of AFC associated with ENaC ([Figure 1(b)](#fig1){ref-type="fig"}). These *ex vivo*data demonstrated that ketamine might decrease transalveolar fluid clearance contributed by ENaC.

3.2. Ketamine Decreases Amiloride-Sensitive Whole-Cell Na^+^ Currents in A549 Cells {#sec3.2}
-----------------------------------------------------------------------------------

Because ketamine decreased amiloride-sensitive fraction of AFC, we postulated that ketamine may directly inhibits ENaC activity. We carried out whole-cell patch clamp studies in A549 cells (a human alveolar epithelial cell line) to further explore the mechanisms for ketamine-reduced AFC.

[Figure 2(a)](#fig2){ref-type="fig"} showed representative recordings of whole-cell currents in the absence and presence of ketamine, ranging from 0 to 1,000 *μ*M in one A549 cell, 10 *μ*M amiloride was then added to compute the amiloride-sensitive currents. Ketamine decreased whole-cell Na^+^ currents at each holding potential in a dose-dependent manner. To compute the IC~50~ value for ketamine, a dose-response curve was plotted with the amiloride-sensitive currents (ENaC activity) measured at cell membrane potential of **−**100 mV ([Figure 2(b)](#fig2){ref-type="fig"}). The minimum value (0 *μ*M) represents the original concentration without drug administration and an IC~50~ value of 63.5 ± 21.7 *μ*M for ketamine was calculated when the data were fitted with the Hill equation. Amiloride-sensitive current density- (ASI~density~-) voltage curves for average control currents (control), in the presence of different concentrations of ketamine (30 *μ*M to 1 mM) were shown in [Figure 2(c)](#fig2){ref-type="fig"}. 100\~1000 *μ*M ketamine could inhibit the amiloride-sensitive Na^+^ currents significantly in patch-clamped A549 cells at each commanding potential (**P** \< 0.05 versus control, **n** = 7). In contrast, even the maximum dosage of DMSO used for dissolving amiloride had no obvious effect (data not shown).

4. Discussion {#sec4}
=============

In this paper, we studied the effects of ketamine on human alveolar epithelial fluid clearance which has important clinical significance. First, several case reports have shown that ketamine is a possible reason for lung edema in patients during intraoperative period \[[@B1]--[@B3], [@B5]\]. If this effect occurred at the level of the alveolar or distal airway epithelium, then the threshold for developing alveolar edema could be downregulated or the resolution of edema, in which active ion transport plays an important role, might be reduced by ketamine \[[@B8]\]. In addition, ketamine is widely used for analgosedation in patients with cardiac and hemodynamic instability who are liable to the occurrence of lung edema. In these patients, the decreased of AFC is associated with increased mortality \[[@B12]\]. Much effort has therefore been focused on identifying the pathogenic mechanisms underlying disturbed AFC in patients and how AFC can be maintained.

4.1. Ketamine Inhibits Fluid Resolution in Human Lungs {#sec4.1}
------------------------------------------------------

To investigate whether ketamine inhibited alveolar Na^+^ transport in the human lung, AFC was measured by a way of fluid instillation. In this setup, the rate of *ex vivo*AFC was significantly reduced in human lobes intratracheally administrated ketamine. Addition of amiloride to the instillate decreased AFC by about 50%, which is in accordance with previous studies \[[@B17], [@B18], [@B22], [@B24]\]. Previous studies showed that S-ketamine via *iv* at clinically relevant bolus concentrations does not affect AFC in rats \[[@B25]\], the difference might result from the many divergent properties of ENaC between different species. For example, cpt-cGMP activates human but not murine ENaC activity \[[@B22]\]. The responses to cpt-cAMP are different between human and murine ENaC, too \[[@B26]\]. It is conceivable that ketamine may reduce ENaC activity in human lungs but may not alter rat counterpart.

Then whether ketamine acts directly on transepithelial sodium transport? It is well known that alveolar fluid clearance is majorly determined by amiloride-sensitive sodium transport pathway \[[@B27], [@B28]\]. During this study, we applied ENaC-specific inhibitor to identify the contribution of ENaC to the total AFC. Our results showed that ketamine decreased amiloride-sensitive fraction of AFC, which reflects ENaC activity. Ketamine may regulate potassium channels, cystic fibrosis transmembrane conductance regulator, Na^+^-K^+^-ATPase, and other transport pathways that coordinately regulate alveolar fluid balance with ENaC and contribute to alveolar fluid absorption. However, the evidence is not available to date. The effects of ketamine on the other channels mentioned above still await for future studies.

When ketamine was instilled into the lung segments together with amiloride, no further inhibition effect occurred. Because the effect of this combination showed no statistic difference from the effect of each drug alone, these findings demonstrate that ketamine indeed inhibited the amiloride-sensitive component of AFC, suggesting that ketamine and amiloride may both act through the same mechanism, blockade of ENaC competitively. On the other hand, ketamine may also inhibit accessory Na^+^ transport sites that were necessary for the inhibition of amiloride, which could explain the reason why amiloride did not induce an additional decrease of alveolar fluid clearance after administration of ketamine. Ketamine might impair the airspace fluid balance by disturbing both alveolar fluid resolution and turnover in human lungs.

4.2. Ketamine Inhibits Alveolar Ion Transport in A549 Cells {#sec4.2}
-----------------------------------------------------------

Ketamine inhibited alveolar sodium transport in rat pneumocytes \[[@B25]\]. ENaC has been documented in type I and II alveolar cells both physiologically and biochemically. Our *ex vivo* data imply that ketamine may eliminate ENaC activity. To corroborate these observations, we measured ENaC activity in A549 cells (a human type II alveolar cell line). We found that ENaC activity was significantly decreased by ketamine in a dose-dependent manner. Our patch clamp data in A549 cells are in good agreement with the *ex vivo* AFC results. The plasma concentration of ketamine after administration of 2 mg/kg intravenously has been reported to be 1.1 × 10^−4^ M \[[@B29]\]. In our study, the same concentration markedly decreased alveolar AFC in human lungs and amiloride-sensitive currents in A549 cells. Because ketamine is cell permeable, the concentration in alveolar fluid may be close to that in plasma during continuously intravenous infusion. In addition, ketamine-induced lung injury may facilitate the leaking of this anesthesiologic reagent into edematous airspaces. These inhibitory effects of ketamine on ENaC thus are implicated in clinically reported lung edema \[[@B1]--[@B3], [@B5]\]. In addition to the direct inhibitory effects on ENaC, ketamine may cause pulmonary edema by stimulating nervous system \[[@B1], [@B3]\] and increasing pulmonary artery pressure \[[@B30]\].

5. Conclusion {#sec5}
=============

To conclude, our study demonstrated that ketamine can inhibit ENaC and decrease ENaC-associated fluid clearance across the distal lung epithelium, which may be the crucial step of the pathogenesis of ketamine-induced pulmonary edema.
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![Effects of ketamine on alveolar fluid clearance in isolated human lungs. (a) Lungs were treated with 5% bovine serum albumin dissolved in physiologic saline solution in the absence of drugs (control), in the presence of amiloride (1 mM), ketamine (100 *μ*M), and both (Keta + Amil). %AFC~60~ represents the AFC percentage after 60 min. (b) Amiloride-sensitive (AS) AFC. Average AFC values are presented as the mean ± SEM, one-way ANOVA. \**P* \< 0.05, \*\**P* \< 0.01. *n* = 5-6.](JBB2011-460596.001){#fig1}

![Patch clamp recordings of amiloride-sensitive currents in A549 cells. (a) Representative recordings of amiloride-sensitive current traces in a cell before (control) and after delivery of different concentrations of ketamine (30 *μ*M to 1 mM) to the bath. (b) Concentration-dependent inhibition of whole-cell currents by ketamine. For each cell, inward currents recorded at −100 mV were measured during perfusion with external solutions. Amiloride-sensitive (AS) currents were normalized to the current at −100 mV of control. IC~50~ was calculated by best fitting the raw data points to the Hill equation. Inorm = 1/(1 + (ketamine/IC~50~))^coe^. (c) Amiloride-sensitive current density- (ASI~density~-) voltage curves for average control currents (control), in the presence of different concentrations of ketamine (30 *μ*M to 1 mM). Average values are presented as the mean ± SEM. One-way ANOVA. \***P** \< 0.05, **n** = 7.](JBB2011-460596.002){#fig2}

###### 

Clinical characteristics of patients.

                                  Control (*n* = 6)   Amiloride (*n* = 5)   Ketamine (*n* = 5)   Keta+am (*n* = 5)
  ------------------------------- ------------------- --------------------- -------------------- -------------------
  Age (year)                      60.0 ± 8.6          64.8 ± 11.4           60.0 ± 8.1           50.4 ± 3.9
  Male (%)                        50                  40                    60                   80
  PaO~2~(mmHg)                    87.4 ± 4.5          86.9 ± 6.8            83.7 ± 8.3           90.2 ± 6.0
  VC (L)                          3.3 ± 0.5           3.1 ± 0.9             3.2 ± 0.9            4.2 ± 0.7
  FEV1.0 actual value (L)         2.4 ± 0.4           2.4 ± 0.9             2.7 ± 0.8            3.2 ± 0.5
  FEV~1.0~ actual/predicted (%)   96.3 ± 21.6         108.2 ± 10.7          96.3 ± 17.4          97.3 ± 10.4
  FVC actual value (L)            3.2 ± 0.4           3.1 ± 0.9             3.2 ± 0.9            3.8 ± 0.6
  FVC actual/predicted (%)        103.6 ± 27.8        113.0 ± 24.1          92.5 ± 9.6           87.5 ± 4.8
  FEV~1.0~/FVC (%)                74.6 ± 10.3         77.9 ± 7.9            84.0 ± 10.0          83.9 ± 3.8

VC: vital capacity; FEV~1.0~: forced expiratory volume in 1.0 s; FVC: forced vital capacity. One-way ANOVA.
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